New research from the Karolinska Institutet highlights links between common exposures and population health, with implications for public‑health surveillance and policy. Using national health registers, surveys and advanced data analyses, Cecilia Magnusson, newly appointed professor of social medicine, has examined how products such as white snus and treatments such as menopausal hormone therapy influence disease risk, and how the incidence of autism varies across population groups.
Key findings and approach
Magnusson’s work draws on Swedish registers and large‑scale epidemiological methods to assess associations between exposures and disease. Her published results include:
- White snus is associated with an increased risk of type 2 diabetes.
- Menopausal hormone therapy is linked to a raised risk of breast cancer.
- The observed rise in autism diagnoses in Sweden is likely to reflect societal change rather than a simple biological surge in incidence.
“Our hypothesis is that people’s health is shaped by their all‑round life situation,”
That holistic perspective sits at the centre of Magnusson’s research agenda. She told Karolinska that the aim of her work is to improve both the quality and the equality of public health and healthcare, and to enable politicians and authorities to identify potential threats early.
Career background
According to Karolinska’s announcement, Cecilia Magnusson was born in Södertälje in 1971 and earned her medical degree in Uppsala in 1995. She completed a PhD at Karolinska Institutet in 1998 with a thesis on breast cancer epidemiology and hormone‑related factors. Magnusson became Professor of Social Medicine at the Department of Global Public Health on 15 October 2025 and combines the professorship with a role as senior physician in community medicine at Region Stockholm’s Centre for Epidemiology and Community Medicine. She is scheduled to participate in the institute’s installation ceremony at Aula Medica on 8 October.
Implications for public health policy and practice
The research underscores several considerations for health authorities and clinicians:
- Continued monitoring of emerging nicotine products, including non‑smoked forms, for metabolic and cardiovascular effects.
- Careful risk‑benefit discussion when prescribing menopausal hormone therapy, taking individual breast cancer risk into account.
- Recognition that diagnostic trends for conditions such as autism may reflect changing awareness, criteria and access to services, not solely epidemiological shifts.
| Exposure | Observed association |
|---|---|
| White snus | Increased risk of type 2 diabetes |
| Menopausal hormone therapy | Increased risk of breast cancer |
| Autism diagnoses | Rise likely reflects societal change |
The findings illustrate how population registers and epidemiological research can inform preventive measures and health service planning. For South Africa, where novel nicotine products and debates about hormone therapy are also present, such international evidence can help inform surveillance priorities and clinical counselling.
Experts emphasise that association does not necessarily equate to causation and that individual decisions about treatments or product use should be made with healthcare professionals. Readers are advised to consult their doctor or local clinic for personalised medical advice rather than self‑diagnosing or changing therapy based solely on population studies.
This report is based on Karolinska Institutet’s profile and summary of Cecilia Magnusson’s research and career.
